A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report

被引:0
作者
Strach, Magdalena [1 ,3 ]
Kuszmiersz, Piotr [1 ]
Chmura, Lukasz [2 ]
Korkosz, Mariusz [1 ]
机构
[1] Jagiellonian Univ Med Coll, Fac Med, Dept Rheumatol & Immunol, Krakow, Poland
[2] Jagiellonian Univ Med Coll, Fac Med, Dept Pathomorphol, Krakow, Poland
[3] Jagiellonian Univ Med Coll, Dept Rheumatol & Immunol, Jakubowskiego 2, PL-30688 Krakow, Poland
关键词
anti-interleukin-6; antibody; case report; diagnosis; idiopathic multicentric Castleman disease; siltuximab; SILTUXIMAB; ONSET;
D O I
10.1002/ccr3.7981
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Key Clinical MessageIdiopathic multicentric Castleman disease (iMCD) is challenging to diagnose due to clinical similarities with other conditions, such as Still's disease. Once diagnosed, iMCD may be effectively managed with the anti-interleukin-6 antibody siltuximab.AbstractHere, we present the case of a 19-year-old Polish woman with persistent fever and enlarged lymph nodes and whose diagnosis remained inconclusive following initial clinical assessments and extensive laboratory analyses. The patient had subsequent complaints of joint pain and erythema which were suspicious of Still's disease and resolved with treatment with tocilizumab. Later, the progression of symptoms, such as lymphadenopathy, and elevated interleukin-6 levels were consistent with Castleman disease, leading to the diagnosis of idiopathic multicentric Castleman disease seven years after the patient first reported symptoms. Treatment with the anti-interleukin-6 antibody siltuximab resulted in complete symptom resolution and normalization of inflammatory parameters. No adverse events were reported due to treatment with siltuximab.
引用
收藏
页数:6
相关论文
共 27 条
[1]   How We Manage Idiopathic Multicentric Castleman Disease [J].
Brandstadter, Joshua D. ;
Fajgenbaum, David C. .
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (09) :564-571
[2]   Castleman disease [J].
Carbone, Antonino ;
Borok, Margaret ;
Damania, Blossom ;
Gloghini, Annunziata ;
Polizzotto, Mark N. ;
Jayanthan, Raj K. ;
Fajgenbaum, David C. ;
Bower, Mark .
NATURE REVIEWS DISEASE PRIMERS, 2021, 7 (01)
[3]  
CASTLEMAN B, 1956, CANCER-AM CANCER SOC, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO
[4]  
2-4
[5]   Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease [J].
Chrysochoou, Stamatios ;
Kreft, Andreas ;
Schneider, Eberhard .
CASE REPORTS IN HEMATOLOGY, 2022, 2022
[6]   Overview of Castleman disease [J].
Dispenzieri, Angela ;
Fajgenbaum, David C. .
BLOOD, 2020, 135 (16) :1353-1364
[7]  
European Medicines Agency, 2019, Sylvant Summary of Product Characteristics
[8]  
European Medicines Agency, 2013, ROACTEMRA SUMM PROD
[9]  
European Medicines Agency, 2008, MabThera Summary of Product Characteristics
[10]   Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease [J].
Fajgenbaum, David C. .
BLOOD, 2018, 132 (22) :2323-2330